PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

U Alberta finds weakness in armor of killer hospital bacteria

University of Alberta researchers found a chink in the molecular armor of the pathogen Acinetobacter baumannii

2012-06-08
(Press-News.org) There's new hope for development of an antibiotic that can put down a lethal bacteria or superbug linked to the deaths of hundreds of hospital patients around the world.

Researchers from the University of Alberta-based Alberta Glycomics Centre found a chink in the molecular armour of the pathogen Acinetobacter baumannii. The bacteria first appeared in the 1970's and in the last decade it developed a resistance to most antibiotics.

U of A microbiologist Mario Feldman identified a mechanism that allows Acinetobacter baumannii to cover its surface with molecules knows as glycoproteins.

Feldman and his team then discovered that if the superbug cannot produce glycoproteins they become less virulent and less capable of forming biofilms, which protect the bacteria from antibiotics.

Feldman says more work is required to understand how the bacteria produces glycoproteins. The researchers say that will enable future development of drugs to interrupt the production of glycoproteins, reducing the bacteria's ability to shield it from antibiotics.

Acinetobacter baumannii is a particularly insidious and contagious pathogenic bacteria that has plagued hospitals around the world. It spreads from one person to another by physical contact. The bacteria can live on hard surfaces for several days and can cling to hospital equipment like catheter tubes and inhalers. Acinetobacter baumannii is also spread by coughing and sneezing.

Hospital patients whose immune systems are already worn down are the most susceptible to Acinetobacter baumannii. It infects wounds and can spread to the lungs, blood and brain.

Feldman is a principal investigator for the Alberta Glycomics Centre at the U of A. He was assisted by U of A graduate students Jeremy Iwashkiw and Brent Weber along with research colleagues in Ottawa, Austria and Australia. Their work was published June 7 in the journal PLoS Pathogens.

INFORMATION:

END



ELSE PRESS RELEASES FROM THIS DATE:

Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective

2012-06-08
Berlin, Germany, June 7 2012: Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by €2,595,557 per 272 patients over 3 years (95 percentile range -€2,983,760 to -€2,211,755), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs. The Dutch study, which investigated 272 patients with RA starting adalimumab treatment, measured ...

Treatment with anti-TNFs reduces the risk of cardiovascular events in rheumatoid arthritis

2012-06-08
Berlin, Germany, June 7 2012: Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumour necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid arthritis (RA) respectively, compared to not using anti-TNF therapies (adjusting for background use of methotrexate or other ...

Nearly two-thirds of American osteoporotic hip fractures are seen in the extreme elderly

2012-06-08
Berlin, Germany, June 7 2012: A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled. Via the Nationwide Inpatient Sample (NIS), 4.3 million patients over the age of 65 with osteoporotic hip fractures were studied. Results showed that 67.3% of hip fractures occurred in the extreme elderly, increasing from 172,209 in 1993 to 180,428 in 2008. This ...

Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo

2012-06-08
Berlin, Germany, June 7 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20* response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo. This randomised, placebo controlled, 24 week period of an ongoing Phase III study of 409 patients indicated that more patients treated with both doses of CZP achieved ACR50* and ACR70* response ...

Control of disease activity and biologic treatment increase life expectency in RA patients

2012-06-08
Berlin, Germany, June 7 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs).The study also found the mortality was similar irrespective of the method of action of biologics (anti-tumour necrosis factor drugs [anti-TNFs] or rituximab). Results of the German study ...

Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent

2012-06-08
Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism. "Anti-TNFs, such as infliximab, adalimumab and etanercept have become the treatment of choice for patients with inflammatory rheumatic diseases who ...

Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab

2012-06-08
Berlin, Germany, June 7 2012: Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20*. The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) was carried out in 646 biologic-naïve patients with active RA and inadequate response to methotrexate. ...

Experts call for strong regulation and peer review of military and civilian nuclear programs

Experts call for strong regulation and peer review of military and civilian nuclear programs
2012-06-08
All nuclear energy and weapons programs should be independently regulated and subject to rigorous peer review, according to three experts on nuclear policy. Their comments and recommendations are published in an article entitled, "A Safer Nuclear Enterprise," in the June 8 issue of the journal Science. The authors noted that, despite international diplomatic efforts to prevent the proliferation of nuclear weapons and ensure that nuclear material is protected against theft, there is growing apprehension about terrorists acquiring weapons or nuclear material. "There is ...

CheapCarInsurance.net Explains Why You Should Purchase Rental Car Insurance

2012-06-08
When you are planning a vacation or a trip and you need to rent a car, one of the most important things that you should consider is whether or not you need to buy rental car insurance. When you search for a car rental company online or in person, most salespeople will tell you that you need insurance, while most web pages will tell you that you do not need it. This couldn't be further from the truth. In reality, purchasing rental car insurance for a few extra dollars per day may be one of the most intelligent things that a person can do for themselves. CheapCarInsurance.net ...

CU-Boulder physicists use ultrafast lasers to create first tabletop X-ray device

2012-06-08
An international research team led by the University of Colorado Boulder has generated the first laser-like beams of X-rays from a tabletop device, paving the way for major advances in many fields including medicine, biology and nanotechnology development. For half a century, scientists have been trying to figure out how to build a cost-effective and reasonably sized X-ray laser that could, among other things, provide super-high-resolution imaging, according to Henry Kapteyn, a CU-Boulder physics professor and fellow at JILA, a joint institute of CU-Boulder and the National ...

LAST 30 PRESS RELEASES:

Science briefing: An update on GLP-1 drugs for obesity

Lower doses of immunotherapy for skin cancer give better results

Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

A sound defense: Noisy pupae puff away potential predators

Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

New findings support a chemo-free approach for treating Ph+ ALL

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

[Press-News.org] U Alberta finds weakness in armor of killer hospital bacteria
University of Alberta researchers found a chink in the molecular armor of the pathogen Acinetobacter baumannii